|
|
 |
|
Viewing report
|
|
|
|
CNS Drug Discoveries: Multiple Sclerosis Chapter
Espicom Business Intelligence Ltd, Aug 2008, Pages: 128
Multiple sclerosis
With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an exciting phase of evolution.
The MS market is estimated to be worth almost US$8 billion in 2008, with a growth rate of 10.6% year-on-year. It is the fifth largest segment of the CNS markets considered in this report and has attracted considerable R&D investment from the big pharmaceutical companies, biotechnology companies and specialty pharma.
Over the next six years a number of oral agents are expected to be launched that could drastically change the way in which MS patients are treated. These include: Novartis' fingolimod, Teva's laquinimod, Merck KGaA’s Mylinax (cladribine), sanofi-aventis' teriflunomide and Biogen Idec's BG-12 in Phase III development, and GSK/Mitsubishi Tanabe Pharma's firategrast, MediciNova's ibudilast and Biogen/UCB's CDP323 in Phase II development.
Three companies have taken on the ambitious task of developing vaccines to treat MS and each has adopted a unique approach to addressing the underlying causes of the disease. Orchestra Therapeutic's NeuroVax targets three proteins expressed on T-cell receptors whilst Opexa Therapeutics' Tovaxin uses attenuated autologous cells to stimulant an immune response. Bayhill Therapeutics is developing BHT-3009, a tolerising DNA vaccine. All vaccines are in Phase II development and could reach market by 2012.
Key MS questions answered:
What is the estimated global population for MS in 2014 and what % will be diagnosed and treated?
Which off-patent MS treatments are resistant to generic competition?
Will Biogen Idec, Teva and Merck KGaA be able to defend their leading positions in 5 years time?
There are 7 late-phase pipeline products which target the underlying cause of MS - what are their strengths and weaknesses?
Key products analysed and forecast
BG-12 - Biogen Idec
Campath - Bayer
Fingolimod - Novartis
Lacquinimod - Teva
MBP 8298 - BioMS/Lilly
Mylinax - Merck KGaA
Teriflunomide - sanofi-aventis
Neurelan - Elan/Acorda
MULTIPLE SCLEROSIS CONTENTS
Executive Summary
THE FACTS
What is multiple sclerosis and why are we interested in it?
Patient Statistics
- Incidence, diagnosis rates and treatment; now and in the future
- Multiple sclerosis categories
Patient Model
The treatable multiple sclerosis patient population growth 2007A - 2014E
Drug Growth Drivers
Drug Growth Risks/Dampeners
THE MARKET
Global Multiple Sclerosis Market
Global Sales Split
- The major players
- Players and products in 2007
- Players and products in 2014
CURRENT MS TREATMENTS
- Leading brands
- Current products’ patent exposure
Analysis of Leading Brands
- Disease-modifying agents
Global Sales Forecasts of Current Treatments 2007A - 2014E
NEW DRUGS IN R&D
Analysis of Phase lll Drugs
- Disease-modifying agents
- Multiple sclerosis symptoms
Global Sales Forecasts of Phase lll Multiple Sclerosis Drugs 2007A - 2014E
Analysis of Phase ll Drugs
- Disease-modifying agents
- Vaccines
Global Sales Forecasts of Phase ll Multiple Sclerosis Drugs 2007A - 2014E
Competitor Ratio Analysis - Products
Competitor Ratio Analysis - Companies
- Winners and losers
Discontinuation of Drugs
APPENDICES
Clinical Diagnostic Test for Multiple Sclerosis
Expanded Disability Status Scale
Phase Transition Probability
Patient Model
Global Multiple Sclerosis Drugs Sales 2007A-2014E
Competitor Ratio Analysis Criteria
Also available
CNS Drug Discoveries: What the future holds 2008
Customers who bought this item also bought
CNS Drug Discoveries: What the future holds 2008
New Drug Futures 2009
CNS Drug Discoveries: Parkinson's Disease Chapter
CNS Drug Discoveries: Depression Chapter
CNS Drug Discoveries: Schizophrenia Chapter
Emerging Opportunities with Cannabinoids
Renal Cell Carcinoma Cancer Drug Futures 2010
CNS Drug Discoveries: Alzheimer's Disease Chapter
Obesity Drug Discoveries: what the future holds
Monoclonal Antibodies: what the future holds
|
|
|
|
